Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics

Wall Street analysts expect Haemonetics (HAE) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 35.6%. Revenues are expected to be $327.34 million, down 4.7% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 3.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street.Analysts predict that the 'Net revenues- Plasma' will reach $127.03 million. The estimate indicates a change of -8.4% from the prior-year quarter.The combined assessment of analysts suggests that 'Net revenues- Hospital' will likely reach $147.41 million. The estimate points to a change of +14.1% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Net revenues- Blood Center' of $53.14 million. The estimate suggests a change of -24.3% year over year.View all Key Company Metrics for Haemonetics here>>>Over the past month, Haemonetics shares have recorded returns of +13.5% versus the Zacks S&P 500 composite's +10.6% change. Based on its Zacks Rank #4 (Sell), HAE will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks